Aton, Valeant Pharmaceuticals International deal

Valeant acquired neurology and ophthalmology company Aton for $318 million in cash. Aton shareholders are eligible for undisclosed regulatory and sales-based milestones on undisclosed products. Valeant will retain global rights to the majority of Aton's products. Future development of an undisclosed portion of Aton's pipeline will be co-funded by Cerberus Capital Management L.P., which owned Aton, under a profit-sharing agreement with Valeant. ...